WILMINGTON, Del. - Global biopharmaceutical company AstraZeneca (NASDAQ:AZN) announced a $300 million investment in a new facility in Rockville, Maryland, aimed at advancing its cell therapy research and production capabilities. The site will focus on manufacturing T-cell therapies for critical cancer trials and is expected to create more than 150 highly skilled jobs.
Located within a thriving life sciences corridor and in proximity to several universities, the new facility will benefit from the area's rich talent pool. Maryland Governor Wes Moore expressed gratitude for AstraZeneca's commitment, highlighting the investment's alignment with the state's innovation goals and its contribution to maintaining Maryland's leadership in the life sciences sector.
The Rockville facility will be part of AstraZeneca's extensive global manufacturing and supply network, which includes nearly 30 sites across 16 countries. The company's U.S. operations employ over 2,600 full-time employees and deliver more than 9 billion doses of medicines each year.
AstraZeneca's cell therapy portfolio focuses on empowering the immune system's T-cells to combat cancer more effectively. It includes various CAR-T therapies in development, such as AZD5851 for hepatocellular carcinoma and AZD6422 for solid tumors. Additionally, through its subsidiary Neogene Therapeutics, AstraZeneca is working on novel T-cell receptor therapies (TCR-Ts) for solid tumors.
The investment in the Rockville site is part of AstraZeneca's broader strategy to lead in next-generation cell therapy and expand its oncology cell therapy portfolio. This effort includes collaborations with companies like Quell Therapeutics, AbelZeta, and Cellectis, and the acquisition of Neogene Therapeutics.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.